Tariot 2009.

Methods	Double‐blind, randomized, placebo controlled trial
Participants	‐ aged 50 years or older ‐ diagnosis of Alzheimer's disease according to DSM‐IV‐TR and NINCDS‐ADRDA criteria ‐ stable on 10 mg donepezil (and no other ChEIs or memantine) for at least 60 days prior to enrolment ‐ not currently taking H1 receptor antihistamines, dextromethorphan or narcotic analgesics within 15 days prior to enrolment
Interventions	Participants were randomized to either: ‐ latrepirdine (20 mg PO TID) for 28 days ‐ matched placebo Enrolment: 24 patients randomized (15 to latrepirdine, 9 to placebo)
Outcomes	Safety and tolerability ‐ discontinuation ‐ frequency and severity of adverse events ‐ changes in vital signs ‐ changes in laboratory values ‐ changes in ECG results
Notes	Funding: Medivation Inc. and Pfizer Inc.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"randomized to treatment with dimebon or placebo in an approximately 2:1 ratio"
Allocation concealment (selection bias)	Unclear risk	This information has not been made available
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"double‐blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	"double‐blind"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Only one subject dropped out of the study, though the reasons were not provided
Selective reporting (reporting bias)	High risk	The authors did not report on all safety outcome measures in their poster presentation of this study
Other bias	Unclear risk	There were no other major sources of bias